Cytokinetics, Incorporated (CYTK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Core Insights - The launch of MYQORZO has been ongoing for about a month, with early signs being encouraging [1] - Key metrics are being monitored, with a focus on awareness among targeted cardiologists [1] Group 1: Launch Metrics - MYQORZO was launched in late January, and the company is only a month into the launch [1] - Over 90% awareness of MYQORZO has been reported among high-volume prescribers of Camzyos, indicating strong recognition in the target market [1]